Reverse mergers attract top-tier biotechs in sluggish IPO market

Article Abstract:

Private biotechs and even a few top-tier private companies are announcing reverse mergers in 2006 as the valuations and market performance have plummeted and several biotech companies have little chance at an initial public offering (IPO). With the Securities and Exchange Commission (SEC) tightening rules, reverse mergers have become validated as a way of raising funds.

Financial management, Finance, United States. Securities and Exchange Commission, Company financing

---

Biotechs await IPO 'boomlet'

Article Abstract:

Several US based biotechs announced initial public offerings (IPO), which resulted in private funds and venture capitalists locked into biotech investments. Most analysts are of the opinion that the boom in biotech is likely to be strictly limited to firms with products that are nearing market approval.

---

More biotechs gamble on convertibles

Article Abstract:

Some biotechnology companies are utilizing convertible securities in order to raise needed funds, but businesses with little revenue risk losing ownership if the value of their stock drops.

Biochemistry, Research and Development in the Physical, Engineering, and Life Sciences, Market information - general

Similar abstracts:

• Abstracts: Brand salience and customer defection in subscription markets. The use of metaphor in exploration of the brand concept
• Abstracts: Diversify to multiply. A special biotech speculation. Splurge or merge?
• Abstracts: Chinese President visits airbus, seeks closer relationship. Thales may acquire German submarine maker
• Abstracts: Cyber surveys come of age. Practice makes perfect
• Abstracts: Push here for fun. The latest in validator technology. Dance to the music

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.